Furthermore, 11 days after tumor rechallenge, the proportion of IFN-γ positive CD8+ T cells in TDLNs of the GC + PTT treated mice (17.3%) was 1.5-fold higher than that in the PBS + PTT (11.7%) or control mice (9.3%), as shown in Figure 3G. There was no difference between the proportions of these cells in the PBS + PTT and control mice (Figure 3G). The gene discussed is CD8A; the disease is neoplasm.